what is the fda deadline for glp-1 drugs Compounded" | Health Communication Research Laboratory FDA warns about unapproved GLP-1

GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d

Supports gut lining integrity

World Health Organization

This targeted microbiome approach reflects growing research connecting gut health with metabolic balance and long-term wellness

Diabetes mellitus is a major risk factor for both cardiovascular and chronic kidney disease (CKD) while CKD is also associated with cardiovascular morbidity

This article reviews the efficacy and safety of different strategies to initiate and intensify basal insulin, with focus on new fixed ratio combinations of basal insulin with GLP-1 RAs available for use in a single injection pen (insulin degludec/liraglutide and insulin glargine/lixisenatide).